Commercial Medicines

The Group acquires global rights to niche hospital-only and critical care products, revitalising these assets around the world and returning them back to sustained growth. The Group also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.

The Group also has an ‘unlicensed to licensed’ (‘UL2L’) strategy, where it looks to take unlicensed medicines with commercial potential and licences them, helping to address unmet medical need and allowing the Group to capitalise on its market-leading positions.

46%

OF ADJUSTED GROUP GROSS PROFIT

MARKET DRIVERS

  • Portfolio rationalising by large pharmaceutical companies
  • Clients increasingly looking to rationalise territories and partner with regional specialists to manage the lifecycle of products
  • Increased pressure to have products available as licensed products by regulatory authorities, HCPs and patients
  • Capability to convert unlicensed medicines to licensed medicines

CLINIGEN RESPONSE AND DIFFERENTIATORS

  • Broad and embedded relationships with pharmaceutical companies
  • Proven revitalisation capability
  • Expert pharmacovigilance, quality management knowledge and understanding of complexity of regulatory environment
  • Capability to convert unlicensed medicines to licensed medicines

Unlicensed Medicines

Clinigen is the global market leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programs to innovative new medicines and provides ‘on-demand’ access globally to medicines which remain unlicensed at the point of care.

44%

OF ADJUSTED GROUP GROSS PROFIT

MARKET DRIVERS

  • Increased role of patient advocacy groups
  • Clients increasingly requiring a global solution
  • Demand for Real World Data (‘RWD’)
  • Clients increasingly wanting a partner to manage supply and distribution beyond early access

CLINIGEN RESPONSE AND DIFFERENTIATORS

  • Consultation capability to advise of policy
  • Global supply chain and distribution network
  • Online proprietary medicines access platform
  • Ability to manage unlicensed supply from early access to ‘on-demand’ access

Clinical Trial Services

CTS is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials (‘IITs’).

10%

OF ADJUSTED GROUP GROSS PROFIT

MARKET DRIVERS

  • Growth in IITs
  • Efficacy to be shown against latest marketed product
  • Clients increasingly require more complex solutions
  • Speed to market launch is becoming a priority

CLINIGEN RESPONSE AND DIFFERENTIATORS

  • Global supply chain and distribution network
  • Certify product for authenticity
  • Expanded services and IIT offering
  • Broad and embedded relationships with pharmaceutical companies